Latest News

New influx of Humira biosimilars may not drive immediate change


 

Educating, advising patients

Dr. Oldfield advised that gastroenterologists refer to biologics by the generic name rather than branded name when initiating therapy unless there is a very specific reason not to. “This approach should make the process more streamlined and less subjected to quick denials for brand-only requests as biosimilars start to assume a larger market share,” he said.

Uptake of the Humira biosimilars also will depend on proper education of physicians and patients and their comfort level with the biosimilars, said Dr. Regueiro. Cleveland Clinic uses a team approach to educate on this topic, relying on pharmacists, clinicians, and nurses to explain that there’s no real difference between the reference drug and its biosimilars, based on efficacy and safety data.

Physicians can also direct patients to patient-friendly resources, said Mr. Newmark. “By starting the conversation early, it ensures that when/if the time comes that your patient is switched to or chooses a biosimilar they will feel more confident because they have the knowledge to make decisions about their care.”

The Global Healthy Living Foundation’s podcast, Breaking Down Biosimilars , is a free resource for patients, he added.

It’s important that doctors also understand these products so they can explain to their patients what to expect, said the FDA’s Dr. Yim. The FDA provides educational materials on its website, including a comprehensive curriculum toolkit.

Dr. Hanauer has served as a consultant for AbbVie, Amgen, American College of Gastroenterology, GlaxoSmithKline, American Gastroenterological Association, Pfizer, and a host of other companies . Dr. Regueiro has served on advisory boards and as a consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, BMS, Organon, Amgen, Genentech, Gilead, Salix, Prometheus, Lilly, Celgene, TARGET Pharma Solutions,Trellis, and Boehringer Ingelheim Pharmaceuticals. Dr. Wolf, Dr. Yim, Dr. Oldfield, and Mr. Newmark have no financial conflicts of interest.

Pages

Recommended Reading

Green Mediterranean diet lowers visceral adipose tissue
MDedge Rheumatology
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
MDedge Rheumatology
A patient named ‘Settle’ decides to sue instead
MDedge Rheumatology
Canadian guidance recommends reducing alcohol consumption
MDedge Rheumatology
New cancer data spark outcry from patient advocates
MDedge Rheumatology
First Humira biosimilar launches in U.S.
MDedge Rheumatology
Vibrating pill can help treat constipation
MDedge Rheumatology
UnitedHealthcare tried to deny coverage to a chronically ill patient. He fought back, exposing the insurer’s inner workings.
MDedge Rheumatology
Health plans get very poor scores for access to autoimmune drugs
MDedge Rheumatology
Joint effort: CBD not just innocent bystander in weed
MDedge Rheumatology